Devon Energy Completes All-Stock Merger with Coterra Energy, Creating $58B Shale Giant
Devon Energy and Coterra Energy completed their all-stock merger on 7 May 2026, with shareholders approving the combination at special meetings on 4 May. Each Coterra share converted into 0.70 Devon shares; Devon holders retain approximately 54% of the enlarged group. The combined company targets $1 billion in annual pre-tax synergies by 2027, anchored by a leading position in the Delaware Basin.
Amazon to Acquire Globalstar for $11.6B to Build Amazon Leo Satellite Network
Amazon agreed on 14 April 2026 to acquire satellite operator Globalstar in an $11.6 billion all-cash deal at $90 per share, enabling the creation of Amazon Leo — a direct-to-device LEO satellite network. Amazon simultaneously announced a partnership with Apple to power satellite-based Emergency SOS services for iPhone and Apple Watch. Close is expected in 2027 pending FCC spectrum and antitrust approvals.
Allegiant Set to Close $1.5B Sun Country Airlines Acquisition as Shareholder Votes Near
Allegiant Travel Company and Sun Country Airlines held shareholder special meetings on 8 May 2026 ahead of an anticipated closing as early as 13 May. The $1.5 billion all-cash and stock deal — announced in January 2026 — cleared DOT regulatory approval in April and received early HSR termination. The combined airline will serve approximately 22 million customers across nearly 175 cities.
Gilead Sciences Acquires ADC Biotech Tubulis for Up to $5B to Expand Oncology Pipeline
Gilead Sciences agreed on 7 April 2026 to acquire Munich-based antibody-drug conjugate biotech Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones. Tubulis's lead asset TUB-040 targets NaPi2b-expressing tumours, showing a 59% overall response rate in platinum-resistant ovarian cancer. The deal is part of Gilead's broader pivot toward oncology through a string of spring 2026 acquisitions.
Gilead Sciences Acquires CAR-T Developer Arcellx for $7.8B in Haematology Push
Gilead Sciences closed its $7.8 billion acquisition of CAR-T therapy developer Arcellx in April 2026. Arcellx's lead asset anito-cel targets relapsed/refractory multiple myeloma — a competitive indication — with Phase 3 data and an expected FDA filing later this year. Post-close, Gilead trimmed approximately 192 positions at Arcellx's Redwood City and Rockville sites as integration began.
FCC Approves Charter's $34.5B Cox Acquisition — California Remains Final Hurdle
The FCC Wireline Competition Bureau approved Charter Communications' $34.5 billion acquisition of Cox Enterprises on 27 February 2026, creating the largest US internet service provider with over 37 million broadband subscribers. The approval came with job protection commitments including a $20/hour minimum wage and onshoring of all offshore functions. California's Public Utilities Commission remains the sole outstanding approval ahead of a September 2026 deadline.
Gilead Sciences Acquires Ouro Medicines for $2.18B to Enter T-Cell Engager Autoimmune Market
Gilead Sciences agreed in April 2026 to acquire Ouro Medicines for up to $2.18 billion, gaining a novel T-cell engager platform targeting autoimmune diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. The deal marks Gilead's entry into immunology beyond its virology roots and completes a six-week acquisition spree — alongside Arcellx and Tubulis — that will generate $11.5 billion in 2026 acquisition charges.